Samsung BioLogics signed a contract with GI Innovation for immunochemotherapy services at its headquarters in Incheon, South Korea. GI Innovation signed this second contract with Samsung BioLogics based the high quality and production services for their first project with Samsung in June of last year.

This agreement is part of a multi-project deal under which Samsung BioLogics will provide contract services from the development of cell lines to the production of Phase I drug substances for GI Innovation. GI is a bio-venture company exploring the development of new drugs through the combination of microbiome (human microorganism) and protein drugs.

This deal is expected to further leverage Samsung BioLogics technology and capacity with GI Innovation’s candidates to help accelerate new drug development.

“As Samsung BioLogics provides consistent services for contract research, contract development and contract manufacturing, biopharmaceutical companies will dramatically reduce costs and time,” said Dr. Tae Han Kim, “We will do our best to help domestic bio-venture companies, including GI Innovation, advance into the global market and commercialize their products through our development technology.”

“Thanks to Samsung BioLogics’ CDMO business, we can overcome the problem of producing high quality clinical test samples, the biggest barrier of bio venture companies,” said Soo Yeon Nam of GI Innovation, “We are very positive that global pharmaceutical companies interested in the R&D pipeline of GI Innovation will be able to access global new drug licensing (BLA) and biotech drug business through Samsung BioLogics’ CDMO service. Through this collaboration, we wish to demonstrate the win-win model of venture firms and large corporations that the people and the government want.”

In 2018, Samsung BioLogics launched its contract development business and has since secured new drug development projects comprising eight domestic and overseas companies, including GI Innovation.